Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, (Q40308157)
Jump to navigation
Jump to search
scientific article published on March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, |
scientific article published on March 2017 |
Statements
1 reference
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, (English)
1 reference
Danielle Porter
1 reference
Jean-Michel Molina
1 reference
Edwin DeJesus
1 reference
Moti Ramgopal
1 reference
Gordon Crofoot
1 reference
Peter Ruane
1 reference
Anthony LaMarca
1 reference
Anthony Mills
1 reference
Claudia T Martorell
1 reference
Joseph de Wet
1 reference
Hans-Jürgen Stellbrink
1 reference
Frank A Post
1 reference
Ignacio Pérez Valero
1 reference
YaPei Liu
1 reference
Andrew Cheng
1 reference
Erin Quirk
1 reference
Devi SenGupta
1 reference
Huyen Cao
1 reference
1 March 2017
1 reference
1 reference
e205-e213
1 reference
Identifiers
1 reference